ASSOCIATION OF LEUCINE-RICH ALPHA-2-GLYCOPROTEIN 1 WITH HUMAN UTERINE LEIOMYOMA

Main Article Content

Dr Madeeha Shahzad Lodhi
Dr Shazia Siddique
Dr Maleha Asim
Dr Anum Yousaf
Dr Zareen Akhter
Firza Fatima

Keywords

Leucine-rich α2-glycoprotein 1, Uterine leiomyoma

Abstract

Background: Uterine leiomyoma, also known as fibroids, is a common benign tumor that affects women of reproductive age. The pathogenesis of uterine leiomyoma involves various molecular and hormonal factors. Leucine-rich α2-glycoprotein 1 (LRG1) and afamin have emerged as potential biomarkers with potential roles in the development and progression of uterine leiomyoma.


Objective: This study aimed to investigate the correlation of serum levels of LRG1 with uterine leiomyoma and assess their potential as biomarkers for the condition.


Methodology: A case-control study was conducted, including 63 cases with uterine leiomyoma and 30 controls without the condition. The participants' demographic data, including age, marital status, occupation, body mass index (BMI), and parity status, were collected. Serum levels of LRG1 were measured using enzyme-linked immunosorbent assays. The size of fibroids was assessed through imaging techniques.


Results: The mean age of the cases and controls was 39.52±6.64 and 37.80±5.89 years, respectively. Among cases 63(100%) and controls 30(100%) all were married. None of them were unmarried. The mean BMI of case and controls was 23.34±3.89 and 23.35±1.76 respectively. The most commonly reported symptom was heavy per vaginal bleeding, which was observed in 30 cases, accounting for 47.62% of the total cases. Parity status of cases showed that 13(20.6%) cases were multiparous, 15(23.8%) were primi-parous and 35(%) were multiparous Mean fibroids size among cases was 26.72±23.15. Among cases mean Leucine rich α2-glycoprotein 1 level was higher as compared to controls.


Conclusion: This study suggests that serum levels of LRG1 serve as reliable diagnostic markers for uterine leiomyoma. These findings contribute to the existing knowledge about the pathophysiology of uterine leiomyoma and highlight the potential involvement of LRG1 in the progression of this condition.

Abstract 201 | pdf Downloads 54

References

1. Abd Elfatah Agameia, R. S. S., El Sokkary, H. H., & Elsayed, G. S. (2021). Study of leucine-rich alpha-2-glycoprotein-1 marker serum level in cases of malignant epithelial ovarian tumors. International Journal of Reproduction, Contraception, Obstetrics and Gynecology, 10(1), 13.
2. Afkarian, M., Zelnick, L. R., Ruzinski, J., Kestenbaum, B., Himmelfarb, J., de Boer, I. H., & Mehrotra, R. (2015). Urine matrix metalloproteinase-7 and risk of kidney disease progression and mortality in type 2 diabetes. Journal of Diabetes and its Complications, 29(8), 1024-1031.
3. Kapp, D. S., Shin, J. Y., & Chan, J. K. (2008). Prognostic factors and survival in 1396 patients with uterine leiomyosarcomas: emphasis on impact of lymphadenectomy and oophorectomy. Cancer, 112(4), 820-830.
4. Karmon, A. E., Cardozo, E. R., Rueda, B. R., & Styer, A. K. (2014). MicroRNAs in the development and pathobiology of uterine leiomyomata: does evidence support future strategies for clinical intervention? Human reproduction update, 20(5), 670-687.
5. Afrin, S., El Sabeh, M., Islam, M. S., Miyashita-Ishiwata, M., Malik, M., Catherino, W. H., Akimzhanov, A. M., Boehning, D., Yang, Q., & Al-Hendy, A. (2021). Simvastatin modulates estrogen signaling in uterine leiomyoma via regulating receptor palmitoylation, trafficking and degradation. Pharmacological research, 172, 105856.
6. Fisher, C. Y. (2019). Cyclic perimenstrual pain and discomfort and the role of complementary and alternative medicine in its treatment
7. Freytag, D., Günther, V., Maass, N., & Alkatout, I. (2021). Uterine fibroids and infertility.
8. Diagnostics, 11(8), 1455.
9. Fu, Y., Feng, Q., Zhang, S., & Li, Y. (2019). Application of oxytocin in ultrasound-guided percutaneous microwave ablation for treatment of hypervascular uterine fibroids: a preliminary report. International Journal of Hyperthermia, 36(1), 760-766.
10. Jokimaa, V., Virtanen, J., Kujari, H., Ala-Nissilä, S., & Rantanen, V. (2020). A Mayer- Rokitansky-Kuster-Hauser patient with leiomyoma and dysplasia of neovagina: a case report. BMC Women's Health, 20(1), 1-6.
11. Kaganov, H., Ades, A., & Fraser, D. S. (2018). Preoperative magnetic resonance imaging diagnostic features of uterine leiomyosarcomas: a systematic review. International journal of technology assessment in health care, 34(2), 172-179.
12. Kajimoto, E., Endo, M., Fujimoto, M., Matsuzaki, S., Fujii, M., Yagi, K., Kakigano, A., Mimura, K., Tomimatsu, T., & Serada, S. (2020). Evaluation of leucine-rich alpha-2 glycoprotein as a biomarker of fetal infection. Plos one, 15(11), e0242076.
13. Kamalipooya, S., Zarezadeh, R., Latifi, Z., Nouri, M., Fattahi, A., & Salemi, Z. (2021). Serum transforming growth factor β and leucine-rich α-2-glycoprotein 1 as potential biomarkers for diagnosis of uterine leiomyomas. Journal of Gynecology Obstetrics and Human Reproduction, 50(3), 102037.
14. Karska, P., Matonog, A., Sieradzka, P., Kowalczyk, K., & Madej, P. (2021). Fresh insight into premature ovarian insufficiency. Ginekologia Polska, 92(7), 518-524.
15. Gao, M., & Wang, H. (2018). Frequent milk and soybean consumption are high risks for uterine leiomyoma: A prospective cohort study. Medicine, 97(41).
16. Gupta, J. K., Sinha, A., Lumsden, M. A., & Hickey, M. (2014). Uterine artery embolization for symptomatic uterine fibroids. Cochrane Database of Systematic Reviews(12).
17. Gupta, S., & Manyonda, I. T. (2009). Acute complications of fibroids. Best practice & research Clinical obstetrics & gynaecology, 23(5), 609-617.